Quantum BioPharma Announces Private Placement to Strengthen Capital Position

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced a non-brokered private placement of up to 30 Class A multiple voting shares at $25 per share, aiming to raise gross proceeds of up to $750. The biopharmaceutical company, which focuses on developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, received shareholder approval for this offering on September 26, 2025. The placement is expected to be fully subscribed by entities controlled by company insiders Zeeshan Saeed and Anthony Durkacz.

The completion of this private placement will significantly impact the company's voting structure, with the voting rights attached to the Class A shares increasing to 75.27%. This restoration brings the voting rights nearly back to their original level when Quantum BioPharma went public in 2018. The company has indicated that the proceeds from this offering will be allocated toward general working capital requirements, providing essential financial support for ongoing operations and development activities.

Quantum BioPharma maintains a diverse portfolio of innovative assets and biotech solutions targeting challenging medical conditions. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing its lead compound, Lucid-MS, a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation represents the underlying mechanism of multiple sclerosis, positioning Lucid-MS as a potentially significant therapeutic advancement for patients suffering from this debilitating neurological condition.

The company's strategic approach extends beyond its core pharmaceutical development through its ownership stake in Unbuzzd Wellness Inc., where Quantum BioPharma retains 20.11% ownership as of March 31, 2025. The relationship includes royalty payments of 7% of sales from the unbuzzd(TM) product until payments to Quantum BioPharma total $250 million, after which the royalty decreases to 3% in perpetuity. Importantly, Quantum BioPharma maintains full rights to develop similar products or alternative formulations specifically for pharmaceutical and medical applications, preserving its flexibility in therapeutic development.

Additional strategic investments are managed through FSD Strategic Investments Inc., another wholly owned subsidiary that represents loans secured by residential or commercial property. This diversified approach to asset management provides the company with multiple revenue streams while it advances its primary pharmaceutical research objectives. Investors seeking additional information about Quantum BioPharma can access the company's newsroom at https://ibn.fm/QNTM.

The private placement announcement comes at a time when biopharmaceutical companies face increasing pressure to secure adequate funding for lengthy and costly drug development processes. For Quantum BioPharma, this capital infusion represents a strategic move to maintain momentum in its research programs while navigating the complex regulatory landscape of drug development. The restoration of voting rights to near-original levels also provides stability in corporate governance as the company progresses its therapeutic candidates through various development stages.